Clinical Trials Logo

Filter by:
NCT ID: NCT05574907 Active, not recruiting - Breast Cancer Clinical Trials

Characterizing Breast Cancer With 68Ga-FAPI PET/CT (PFB-01)

Start date: May 1, 2021
Phase: N/A
Study type: Interventional

Fibroblast activation protein (FAP) is overexpressed in cancer-associated fibroblasts (CAFs), which constitute a major proportion of cells within the tumor microenvironment, especially in breast cancer. 68Ga-FAPI has been developed as a tumor-targeting agent. This prospective study is going to investigate the performance and value of 68Ga-FAPI PET/CT in patients with breast cancer.

NCT ID: NCT05574894 Completed - Growth Hormone Clinical Trials

Effect of GH Supplementation on the Blastocyst Euploid Rate in AMA Patients--A Retrospective Cohort Study

Start date: January 1, 2021
Phase: Phase 3
Study type: Interventional

This retrospective cohort study aims to investigate the effects of recombinant human growth hormone (rh-GH) on the euploid status of preimplantation blastocysts in AMA patients. Infertile patients aged 38-46 years old were recruited for study if they fulfill the inclusion criteria and do not have the exclusion criteria. Treatment group: Women received growth hormone (GH) supplement during antagonist protocol for ovarian stimulation. Control group: Women received antagonist protocol for ovarian stimulation. The primary outcome is the euploidy rate of blastocysts per stimulation cycle and per testing cycle.

NCT ID: NCT05574881 Active, not recruiting - Breast Cancer Clinical Trials

Dalpiciclib, Fulvestrant, Trastuzumab and Pertuzumab in HR Positive, HER2 Positive Metastatic Breast Cancer

Start date: September 1, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

To investigate the efficacy and safety of Dalpiciclib, Fulvestrant, Trastuzumab and Pertuzumab in HR+/HER2+ Metastatic Breast Cancer

NCT ID: NCT05574608 Recruiting - Clinical trials for Acute Myeloid Leukemia Refractory

Allogenic CD123-CAR-NK Cells in the Treatment of Refractory/Relapsed Acute Myeloid Leukemia

Start date: October 1, 2022
Phase: Early Phase 1
Study type: Interventional

The CD123-Targeted CAR-NK cell therapy is a new treatment that is being investigated for treatment of acute myeloid leukemia (AML). The purpose of this study is to evaluate the safety of CD123-CAR NK cells given to these patients.

NCT ID: NCT05574543 Completed - Clinical trials for Degenerative Disc Disease

A Phase I/II Study of AGA111 for Lumbar Interbody Fusion in Patients With Degenerative Disc Disease

Start date: December 1, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

The objectives of the study are to evaluate the safety and preliminary efficacy of a single administration of AGA111 for lumbar interbody fusion in patients with degenerative disc disease.

NCT ID: NCT05574517 Recruiting - Urinary Calculi Clinical Trials

Tubeless Percutaneous Nephrolithotomy Without Reverse Insertion of a Ureteral Catheter

Start date: October 7, 2022
Phase: N/A
Study type: Interventional

Percutaneous nephrolithotomy(PCNL) is a surgical method for upper urinary calculi. The advent of tubeless PCNL (without indwelling nephrostomy tube) has been proved to be safe and effective in reducing postoperative discomfort, shortening hospitalization time and reducing hospitalization costs. Traditional tubeless PCNL usually involves retrograde insertion of the ureteral catheter, which may cause many ureteral related surgical complications. However, there are few reports on tubeless PCNL without reverse ureteral catheter insertion. The goal of this study is to explore the safety and effectiveness of the tubeless PCNL without reverse ureteral catheter insertion.

NCT ID: NCT05573399 Completed - Clinical trials for Pancreatoduodenectomy

Early Oral Feeding for Patients After Pancreaticoduodenectomy

Start date: August 1, 2018
Phase:
Study type: Observational

This study intends to retrospectively analyze the patients who underwent pancreatoduodenectomy and compare the safety and feasibility between early enteral nutrition through nasojejunal tube and early oral feeding after pancreatoduodenectomy. This study is expected to revise the guidelines for early nutritional support after pancreaticoduodenectomy, reduce postoperative complications, and provide better guidance for clinical work.

NCT ID: NCT05573373 Recruiting - Clinical trials for Carcinoma, Non-Small-Cell Lung

Pamiparib (BGB-290) Was Used in EGFR-TkIs Resistant Non-small Cell Lung Cancer

Start date: December 20, 2022
Phase: Phase 1
Study type: Interventional

The purpose of this study was to investigate the efficacy and safety of pamiparib in patients with EGFR-TKIs-resistant NSCLC, using a single-center, dual-arm, open-label design.

NCT ID: NCT05573282 Recruiting - Clinical trials for Hepatocellular Carcinoma

Observation Study of Sequential Regorafenib Plus ICIs After HAIC for Advanced Hepatocellular Carcinoma

Start date: October 16, 2022
Phase:
Study type: Observational

Hepatic artery infusion chemotherapy (HAIC) has shown promising outcomes in patients with advanced hepatocellular carcinoma (HCC). Some patients can be converted to loco-regional therapies after 4-6 cycles of HAIC treatment. But most of these patients still need to concern the sequential treatment after standard HAIC treatment (4-6 cycles). Combination of anti-angiogenic molecular targeted therapy and immune checkpoint inhibitor (ICI) therapy has shown promising antitumor activity in HCC. Regorafenib is one of the standard second-line systemic therapy for advanced HCC. In this study, we will evaluate the efficacy and safety of sequential therapies of Regorafenib plus ICI in patients with advanced HCC who have completed 4-6 cycles of HAIC.

NCT ID: NCT05573191 Not yet recruiting - General Anesthesia Clinical Trials

Effects of Intravenous Lidocaine on ED50, ED95 and NTI Values of Propofol Induced Unconsciousness

Start date: October 8, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

The effect of intravenous lidocaine on ED50 and ED95 of propofol, which causes unconsciousness, is unclear. In addition, it is not clear whether the depth of anesthesia induced by propofol changes when lidocaine is used in combination. Therefore, the purpose of this study was to study the effects of intravenous lidocaine on ED50, ED95 and NTI values of propofol induced unconsciousness .